The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) (“Salix Pharmaceuticals”) in connection with the sale of the Company to a subsidiary of Cosmo Pharmaceuticals S.p.A.

Click here to learn about the case: http://docs.wongesq.com/SLXP-Info-Request-Form-295. There is no cost or obligation to you.

Under the terms of the transaction, Salix Pharmaceuticals shareholders will receive one share of the post-merger entity for each share of Salix Pharmaceuticals they own. The investigation concerns whether the Salix Pharmaceuticals Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Cosmo Pharmaceuticals S.p.A. is underpaying for Salix Pharmaceuticals shares.

If you own common stock in Salix Pharmaceuticals and wish to obtain additional information, please contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/SLXP-Info-Request-Form-295.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010